Hot Pre-Market Trades in US Stocks
BANXR, up 29.88% in pre-market trading, has no significant news recently. The trading is active, with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Us Antimony is up 7.90% in pre-market trading. Based on recent key news:
<ol>
<li>
On February 10, Americas Gold and Silver Corporation reached an agreement with US Antimony Corporation to establish a joint venture. This move aims to enhance resource extraction and processing capabilities, expected to improve production efficiency and output, driving the stock price up. Source: Jin Shi Data
</li>
<li>
On February 10, Antimony Resources Corp. announced that investors exercised 6.1 million stock warrants, raising USD 1.21 million. These funds will be used for exploration activities at the Bald Hill project in Canada, enhancing the company's financial position and boosting market confidence. Source: Newsfile
</li>
<li>
On February 10, the market demand for antimony increased, particularly from government-related needs, driving the stock price up. Source: United States Antimony Corp.
</li>
</ol>
Top Gainers in Pre-Market Trading in US Stocks
Evommune is up 93.05% in pre-market trading. Based on recent key news:
<ol>
<li>
On February 10, Evommune released a press release detailing its latest R&amp;D progress and future plans. The company emphasized its innovative achievements in the treatment of skin diseases in the press release, which triggered a positive market reaction, significantly boosting the stock price. The press release was published via Business Wire, showcasing the company's ongoing investment in scientific research.
</li>
<li>
On February 10, the involvement of Dr. Lebwohl, a member of Evommune's scientific advisory board, was disclosed, further enhancing market confidence in the company's R&amp;D capabilities. Dr. Lebwohl's professional background and experience brought more credibility to the company, leading investors to hold an optimistic view of the company's future development.
</li>
<li>
On February 10, the risk factors mentioned in the company's quarterly report were widely discussed in the market. Despite potential risks, investors remain optimistic about the company's long-term growth potential, resulting in a significant increase in the stock price during pre-market trading. Innovations in the treatment of skin diseases have attracted attention.
</li>
</ol>
Quince Therapeutics is up 75.23% in pre-market trading. Based on recent key news:
<ol>
<li>
On February 10, Quince Therapeutics announced the hiring of LifeSci Capital as a financial advisor to help explore restructuring and strategic alternatives. This move may trigger optimistic expectations in the market regarding the company's future development, leading to a significant increase in the stock price. Source: WSJ
</li>
<li>
On February 10, Quince Therapeutics' stock price rose 91.08% in pre-market trading, despite a 90.71% decline in stock price over the past year. This substantial increase may be a response from the market to the company's strategic adjustments
Source: Benzinga
</li>
</ol>
On February 10, technical indicators showed that Quince Therapeutics was in an oversold state, with an RSI of 22.15, potentially triggering a rebound. Although the MACD still indicated bearish pressure, market expectations for a potential rebound could drive the stock price up. Source: Benzinga The biotechnology industry is facing challenges, with significant capital inflows.
Abpro surged 61.84% in pre-market trading. Based on recent news,
<ol>
<li>
On February 10, Goldman Sachs disclosed a 6.8% stake in Abpro, driving the stock price up. Goldman Sachs, as one of the largest financial investment and banking companies in the United States, has a significant impact on traders.
</li>
<li>
On February 10, Abpro's pre-market trading volume surged to 21 million shares, far exceeding the three-month daily average of 4.5 million shares, indicating strong market interest in the stock.
</li>
<li>
On February 9, Abpro's stock price rose 1.33%, despite a year-to-date decline of 64.07% and a 12-month decline of 94.88%. The market reacted positively to Goldman Sachs' investment, with a significant increase in trading volume
</li>
</ol>

BANXR

UAMY

BANXR pre-market up 29.88%; Us Antimony pre-market up 7.90%; Evommune pre-market up 93.05%; Quince Therapeutics pre-market up 75.23%; Abpro pre-market up 61.84%

Pre-market hot trades in US stocks: BANXR up 29.88% pre-market; Us Antimony up 7.90% pre-market